Board Of Directors And Doing Business In China Under The FCPA

Published date07 August 2013
Law FirmThomas Fox
Subject MatterBoard of Directors,Bribery,China,Compliance,Corruption,FCPA,Foreign Official,GlaxoSmithKline

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT